Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Sat., Mar. 25, 12:17 PM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #69 of 100 |
Slide #69. McKesson — Celesio
Acquirer:
McKesson (NYSE:MCK)
Acquiree:
Celesio
Details:
McKesson Corporation [NYSE: MCK] ("McKesson"), a leading North American healthcare services and information technology company, and Celesio AG [ISIN DE000CLS1001] ("Celesio"), a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors, announced today that McKesson has signed an agreement to acquire a majority stake in Celesio for 23 per share and to launch parallel voluntary public tender offers for the remaining publicly-traded shares and outstanding convertible bonds of Celesio. The offer price of 23 per share represents a 39% premium over the three-month volume weighted average price prior to the market speculation that began on October 8, 2013. The total transaction, including the assumption of Celesio's outstanding debt, is valued at approximately $8.3 billion(6.1 billion)*.
McKesson is engaged in healthcare services. Co. operates its business in four reportable segments: U.S. Pharmaceutical, which distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; Prescription Technology Solutions, which delivers access and adherence solutions as well as dispensing support services, third-party logistics and wholesale distribution support; Medical-Surgical Solutions, which provides medical-surgical supply distribution, logistics, and other services to healthcare providers; and International, which provides distribution and services to wholesale, institutional, and retail customers.
McKesson SEC Filing Email Alerts Service
Open the MCK Page at The Online Investor »
|
|||||||||||||||||||||
Open the MCK Page at The Online Investor (in a new window) »
 Free MCK Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.46 out of 4) 54th percentile
(ranked higher than approx. 54% of all stocks covered)
Analysts' Target Price: MCK Stock Forecast Based on Zacks ABR data; powered by Xignite |
